Holen Sie sich die Stockscreener-App
1,131.81
0.52%
7.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,123.91
Offen:
$1127.61
24-Stunden-Volumen:
146.20K
Relative Volume:
0.05
Marktkapitalisierung:
$1.01T
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
40.74
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
-2.61%
1M Leistung:
-4.72%
6M Leistung:
+12.04%
1J Leistung:
+50.51%
1-Tages-Spanne:
$1,125.81
$1,137.09
1-Wochen-Bereich:
$1,113.55
$1,171.66
52-Wochen-Spanne:
$712.05
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,132.69 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.66 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.74 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.66 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
138.69 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
What Is Shaping Interest in Eli Lilly Stock? (NYSE:LLY) - kalkinemedia.com
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Eli Lilly lawsuit against weight-loss drug seller gets another shave - Courthouse News
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years - Benzinga
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline - kalkinemedia.com
ELI LILLY Executive Vice President Eric Dozier Retains 14,239 Shares Following Gift Transaction - kalkinemedia.com
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? - The Motley Fool
Lilly fighting black market for its next obesity drug - The Indiana Lawyer
Eli Lilly (NYSE:LLY): Can New FDA Approvals Fuel Growth? - kalkinemedia.com
Why Is Eli Lilly Stock Falling Tuesday? - Benzinga
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? - Yahoo Finance
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 14.46% Upside in the Healthcare Giant - DirectorsTalk Interviews
Eli Lilly expands US pharmaceutical manufacturing with over US$50bn investment - Scientist Live
Eli Lilly’s $100B incretin opportunity: Is more upside coming? - Investing.com
Lilly invests SGD $42M in new Digital Health Hub in Singapore - Singapore Economic Development Board (EDB)
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years - The Motley Fool
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. - The Motley Fool
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Lilly looks beyond obesity with $2.88B autoimmune buyout - thestreet.com
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo grow scripts - Fierce Pharma
DRUGS AND BIOLOGICS—5th Cir.: Fifth Circuit upholds FDA's removal of tirzepatide from drug shortage list, rejecting compounders' APA challenges - VitalLaw.com
Eli Lilly and Company $LLY Shares Bought by BNP Paribas - insurancenewsnet.com
Eli Lilly Just Announced a Major Acquisition. Here's What It Means. - The Motley Fool
Eli Lilly’s Foundayo Launches in UK Amid Counterfeit Risks - healthcare-digital.com
Lilly to acquire Merida Biosciences for up to $2.875bn - Manufacturing Chemist
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity - MarketBeat
JPMorgan reiterates Eli Lilly stock rating on incretin growth - Investing.com
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new S$42 million hub in Singapore - Singapore Economic Development Board (EDB)
This New Zepbound Study Could Be Great News for Eli Lilly Investors - The Motley Fool
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal - Yahoo Finance
Lilly to acquire biotechnology company for $2.8B - dailyjournal.net
Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors - Endpoints News
BMO reiterates Eli Lilly stock Outperform on Merida acquisition - Investing.com
Merida Biosciences Acquisition by Eli Lilly for Up to $2.875 Bil - GuruFocus
Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline - Yahoo! Finance Canada
Lilly snags another Massachusetts biotech as local headcount surges past 1,400 - The Business Journals
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion - citybiz
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion - WSJ
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - Eli Lilly
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes - Eli Lilly and Company
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs? - Yahoo Finance
Lilly(Eli) & Co (LLY) Futures: Prices, Contracts & Specs - stocktwits.com
Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement - TradingKey
Eli Lilly launches oral weight-loss drug Foundayo in UK - Reuters
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk (NYSE:LLY) - Seeking Alpha
Novo Nordisk: The Pill That Could Close The Gap With Lilly (NYSE:NVO) - Seeking Alpha
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years - Benzinga
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):